Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 CAR-T-19 study in pediatric and young adult relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia
CTR20234206Phase 2Active
- Sponsor
- Immunotech Biopharm
- Start
- Jan 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARI-0001 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Immunotech Biopharm. Primary endpoint: Overall response rate by independent review committee at 12 weeks. Started Jan 2024; status: active.
02
Drugs
ARI-0001
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on CTR20234206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234206.